Intron retention is a source of neoepitopes in cancer
- 16 August 2018
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 36 (11) , 1056-1058
Abstract
Neoepitopes derived from intron retention events are processed and presented on MHC I in cancer cell lines. We present an in silico approach to identifying neoepitopes derived from intron retention events in tumor transcriptomes. Using mass spectrometry immunopeptidome analysis, we show that retained intron neoepitopes are processed and presented on MHC I on the surface of cancer cell lines. RNA-derived neoepitopes should be considered for prospective personalized cancer vaccine development.Keywords
This publication has 36 references indexed in Scilit:
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerNature, 2017
- An immunogenic personal neoantigen vaccine for patients with melanomaNature, 2017
- MHC class I–associated peptides derive from selective regions of the human genomeJournal of Clinical Investigation, 2016
- Intron retention is a widespread mechanism of tumor-suppressor inactivationNature Genetics, 2015
- Widespread intron retention diversifies most cancer transcriptomesGenome Medicine, 2015
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cellsScience, 2015
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with ResponseClinical Cancer Research, 2015
- Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translationProceedings of the National Academy of Sciences, 2011
- Proteases in MHC Class I Presentation and Cross-PresentationThe Journal of Immunology, 2009
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008